

ORAMED PHARMACEUTICALS INC.  
Form 8-K  
August 05, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **August 2, 2016**

**ORAMED PHARMACEUTICALS INC.**  
(Exact name of registrant as specified in its charter)

**DELAWARE**                      **001-35813**    **98-0376008**  
(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation)              File Number) Identification No.)

**Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel**    **91390**  
(Address of Principal Executive Offices)                                      (Zip Code)

**+972-2-566-0001**

(Registrant's telephone number, including area code)

Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. Entry into a Material Definitive Agreement.**

On August 2, 2016, Oramed Pharmaceuticals Inc. (the "Company"), its Israeli wholly-owned subsidiary and Hefei Tianhui Incubator of Technologies Co. Ltd. executed an amendment (the "Amendment") of the Amended and Restated Technology License Agreement (the "License Agreement") dated December 21, 2015, as previously disclosed in the Company's Current Report on Form 8-K, filed on December 28, 2015. The Amendment is effective as of July 24, 2016 and it replaces the Pre-Commercialization Plan (Exhibit C) and Subsequent Payment arrangements (Exhibit F2) of the License Agreement in order to revise the terms of certain milestones and planning details. All other terms of the License Agreement, including the aggregate maximum payments, remain in full force and effect.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ORAMED  
PHARMACEUTICALS  
INC.**

By: /s/ Nadav Kidron  
Name: Nadav Kidron  
Title: President and CEO

August 5, 2016